In an earlier study this research group reported iprindole, a relatively new tricyclic derivative, to be an effective drug for use in depressed neurotic out-patients (ii). We found it to produce significantly greater improvement than placebo on a variety of outcome measures. Good response to iprindole as compared to placebo has also been reported by Hicks (5) and Daneman (3). Sterlin et al., comparing iprindole with amitriptyline in a relatively small patient sample, reported that iprindole, while faster acting, produced less overall improvement (15); differences in improvement did not, however, reach statistical significance.